

# Daniela Corna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10148877/publications.pdf>

Version: 2024-02-01

78  
papers

6,333  
citations

57758

44  
h-index

69250

77  
g-index

78  
all docs

78  
docs citations

78  
times ranked

6135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF/caveolin-1/PV-1 signaling pathway. <i>Journal of Pathology</i> , 2022, 256, 468-479.	4.5	21
2	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. <i>Journal of Immunology</i> , 2022, 208, 1772-1781.	0.8	2
3	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. <i>Cells</i> , 2022, 11, 1755.	4.1	3
4	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021, 145, 428-444.	1.8	5
5	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. <i>Stem Cell Research</i> , 2021, 55, 102476.	0.7	4
6	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. <i>Scientific Reports</i> , 2021, 11, 23580.	3.3	10
7	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , 2020, 29, 096368972096546.	2.5	1
8	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. <i>Scientific Reports</i> , 2020, 10, 8418.	3.3	51
9	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. <i>JCI Insight</i> , 2020, 5, .	5.0	46
10	<i>Sirt3</i> Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by <i>Opa1</i> Gene Transfer. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1255-1271.	5.4	70
11	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. <i>Kidney International</i> , 2019, 96, 906-917.	5.2	31
12	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. <i>JCI Insight</i> , 2019, 4, .	5.0	21
13	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>JCI Insight</i> , 2018, 3, .	5.0	114
14	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , 2018, 67, 2069-2083.	0.6	8
15	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018, 9, 220.	5.5	26
16	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , 2017, 8, 983.	12.8	124
17	A previously unrecognized role of C3a in proteinuric progressive nephropathy. <i>Scientific Reports</i> , 2016, 6, 28445.	3.3	22
18	Simplified Method to Measure Glomerular Filtration Rate by Iohexol Plasma Clearance in Conscious Rats. <i>Nephron</i> , 2016, 133, 62-70.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016, 132, 59-69.	1.8	36
20	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1400-1411.	6.1	51
21	B7 <sup>1</sup> Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 999-1005.	6.1	30
22	Renal Primordia Activate Kidney Regenerative Events in a Rat Model of Progressive Renal Disease. <i>PLoS ONE</i> , 2015, 10, e0120235.	2.5	17
23	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. <i>Nephron</i> , 2015, 129, 52-61.	1.8	43
24	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1786-1798.	6.1	52
25	Î <sup>2</sup> -Arrestin-1 Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 523-533.	6.1	63
26	Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F808-F819.	2.7	90
27	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. <i>PLoS ONE</i> , 2013, 8, e70775.	2.5	75
28	In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1857-1868.	6.1	156
29	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. <i>Journal of Immunology</i> , 2012, 189, 3661-3668.	0.8	35
30	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F1370-F1381.	2.7	88
31	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1291-F1300.	2.7	13
32	Distinct cardiac and renal effects of ET <sub>A</sub> receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F1114-F1123.	2.7	56
33	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F1203-F1211.	2.7	49
34	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009, 76, 960-967.	5.2	56
35	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1448-F1456.	2.7	114
36	Proteasomal Processing of Albumin by Renal Dendritic Cells Generates Antigenic Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 123-130.	6.1	88

#	ARTICLE	IF	CITATIONS
37	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. <i>Gene Therapy</i> , 2009, 16, 1373-1379.	4.5	13
38	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 524-530.	8.2	434
39	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. <i>Stem Cells</i> , 2008, 26, 2075-2082.	3.2	351
40	Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1158-1167.	6.1	63
41	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. <i>American Journal of Nephrology</i> , 2007, 27, 630-638.	3.1	12
42	Insulin-Like Growth Factor-1 Sustains Stem Cell-Mediated Renal Repair. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2921-2928.	6.1	294
43	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1629-1637.	6.7	46
44	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , 2006, 70, 97-103.	5.2	71
45	Transcriptional Regulation of Nephric Gene by Peroxisome Proliferator-Activated Receptor- $\gamma$ Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1624-1632.	6.1	76
46	Beneficial Effect of TGF $\beta$ 2 Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. <i>Nephron Experimental Nephrology</i> , 2006, 104, e158-e168.	2.2	43
47	Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2666-2674.	6.1	31
48	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004, 66, 1959-1965.	5.2	52
49	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1794-1804.	6.1	690
50	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , 2003, 64, 857-863.	5.2	13
51	Protein Overload Induces Fractalkine Upregulation in Proximal Tubular Cells through Nuclear Factor $\kappa$ B and p38 Mitogen-Activated Protein Kinase-Dependent Pathways. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2436-2446.	6.1	118
52	Add-On Anti-TGF $\beta$ 2 Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1816-1824.	6.1	177
53	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2898-2908.	6.1	156
54	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002, 61, 1635-1645.	5.2	103

#	ARTICLE	IF	CITATIONS
55	Proximal tubular cells promote fibrogenesis by TGF- $\beta$ 1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002, 61, 2066-2077.	5.2	109
56	Angiotensin-Converting Enzyme inhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist. <i>American Journal of Pathology</i> , 2001, 159, 1743-1750.	3.8	45
57	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001, 60, 653-663.	5.2	49
58	17 $\beta$ -Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 279, F626-F635.	2.7	25
59	Protein traffic activates NF- $\kappa$ B gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1226-1241.	1.9	145
60	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. <i>American Journal of Kidney Diseases</i> , 1999, 33, 746-753.	1.9	42
61	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 804-813.	6.1	99
62	Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1542-1549.	6.1	126
63	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy <sup>1</sup> . <i>Kidney International</i> , 1998, 54, 353-359.	5.2	77
64	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with $\alpha$ 3 chain of type IV collagen. <i>Kidney International</i> , 1998, 54, 1550-1561.	5.2	43
65	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. <i>Kidney International</i> , 1998, 53, 726-734.	5.2	71
66	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF- $\beta$ in experimental mesangioproliferative glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1998, 31, 453-463.	1.9	55
67	Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy. <i>Nephron Experimental Nephrology</i> , 1998, 6, 121-131.	2.2	44
68	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , 1997, 29, 254-264.	1.9	74
69	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. <i>Kidney International</i> , 1997, 51, 1583-1589.	5.2	134
70	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. <i>Kidney International</i> , 1997, 52, 171-181.	5.2	138
71	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. <i>American Journal of Kidney Diseases</i> , 1996, 27, 416-423.	1.9	99
72	A Study of Low-Nutrient Diets Used for Aging Studies in the Rat. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1996, 51A, B270-B275.	3.6	2

#	ARTICLE	IF	CITATIONS
73	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. <i>Kidney International</i> , 1993, 44, 440-444.	5.2	215
74	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , 1993, 43, 354-358.	5.2	153
75	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. <i>American Journal of Medicine</i> , 1992, 92, S60-S63.	1.5	31
76	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , 1990, 38, 96-100.	5.2	5
77	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. <i>Journal of Clinical Investigation</i> , 1990, 86, 1768-1771.	8.2	110
78	Sequence of Glomerular Changes in Experimental Endotoxemia: A Possible Model of Hemolytic Uremic Syndrome. <i>Nephron</i> , 1989, 53, 330-337.	1.8	19